| 李瑞麟,程亚卉,孙春萍,韩 晗,张 伟.达格列净联合利拉鲁肽对肥胖型T2DM患者的血糖控制、胰岛素功能的影响及安全性分析[J].,2023,(13):2541-2545 |
| 达格列净联合利拉鲁肽对肥胖型T2DM患者的血糖控制、胰岛素功能的影响及安全性分析 |
| Effect and Safety Analysis of Daglilipine Combined with Liraglutide on Blood Glucose Control and Insulin Function in Obese T2DM Patients |
| 投稿时间：2023-02-06 修订日期：2023-02-28 |
| DOI：10.13241/j.cnki.pmb.2023.13.028 |
| 中文关键词: 肥胖型2型糖尿病 血糖 血压 安全性 |
| 英文关键词: Obese type 2 diabetes mellitus Blood sugar Blood pressure Safety Chinese Library Classification(CLC): R587.1 Document code: A |
| 基金项目:安徽医科大学第三附属医院基础与临床合作研究提升计划培育专项基金（2022sfy012） |
|
| 摘要点击次数: 359 |
| 全文下载次数: 216 |
| 中文摘要: |
| 摘要 目的：探究达格列净联合利拉鲁肽对肥胖型2型糖尿病（T2DM）患者的血糖控制、胰岛素功能的影响及安全性分析。方法：将106例肥胖型T2DM患者按照治疗方法分为两组：联合组患者采用达格列净联合利拉鲁肽治疗（55例）、对照组采用利拉鲁肽治疗（51例）。记录对比两组治疗疗效、不良反应发生情况。检测两组治疗前后血脂代谢指标[脂联素(APN)、总胆固醇（TC）、甘油三酯（TG)]、胰岛素功能指标[稳态胰岛 β 细胞分泌功能指数（HOMA-β）、胰岛素评价指数（HOMA-IR）]、血压[收缩压（SBP）、舒张压（DBP）]以及身体质量指数（BMI）变化。结果：联合组治疗总有效率高于对照组（P＜0.05），不良反应总发生率高于对照组（P＜0.05）。治疗后，观察组外周血TC、TG水平、HOMA-IR以及SBP、DBP低于对照组（P＜0.05），APN浓度、HOMA-IR以及BMI高于对照组（P＜0.05）。结论：达格列净联合利拉鲁肽可有效控制肥胖型T2DM患者的血糖、血脂以及血压水平，保护胰岛功能，但也可能导致更多的不良反应。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effect and safety of Daglilipin combined with Liraglutide on blood glucose control and insulin function in patients with obese type 2 diabetes mellitus (T2DM). Methods: A total of 106 obese T2DM patients were divided into two groups according to treatment methods: combination group was treated with dagliagliazine combined with liraglutide (55 cases), and control group was treated with liraglutide (51 cases). The therapeutic effect and the occurrence of adverse reactions were recorded and compared between the two groups. Lipid metabolism indexes (adiponectin (APN), total cholesterol (TC), triglyceride (TG) and insulin function indexes (homeostasis islet β) were detected before and after treatment in the two groups Changes in cell secretion function index (HOMA-β), insulin evaluation index (HOMA-IR), blood pressure [systolic blood pressure (SBP), diastolic blood pressure (DBP)] and body mass index (BMI). Results: The total effective rate of combined group was higher than that of control group (P<0.05), and the total incidence of adverse reactions was higher than that of control group (P<0.05). After treatment, the levels of TC, TG, HOMA-IR and SBP, DBP in peripheral blood of the observation group were lower than those of the control group(P<0.05), while the concentration of APN, HOMA-IR and BMI were higher than those of the control group(P<0.05). Conclusion: Dagliagliazine combined with Liraglutide can effectively control the levels of blood glucose, blood lipid and blood pressure in obese T2DM patients, protect the function of the islet, but may also lead to more adverse reactions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
